DT-9046 / Domain Therap - LARVOL DELTA

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases (PRNewswire) - "Domain Therapeutics...today announces it has nominated and is progressing DT-9046, a candidate with game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine....DT-9046 is currently progressing through pre-IND studies, supported by a robust data package and strong patent protection. Preclinical studies have demonstrated potent and selective modulation of the immune response, which plays a crucial role in various inflammatory conditions, particularly in AD and IBD."

Pipeline update • Preclinical • Atopic Dermatitis • Inflammatory Bowel Disease • Migraine